- Conditions
- Alzheimer's Disease
- Interventions
- Psilocybin, Cognitive Training
- Drug · Other
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 65 Years to 120 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Condition Directory
Alzheimer's Disease clinical trials
Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 21, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
2117
Shown on this page
12
Local recruiting
5
Local phase groups
4
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Alzheimer's Disease studies are organized in the registry
The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.
- 45% of the 11 locally indexed Alzheimer's Disease records are currently marked recruiting.
- The most common phase group in the local index is Phase 3 (7 records).
- The most frequent sponsor is Hoffmann-La Roche (4 records).
- The most listed study location is Dallas, Texas (8 records).
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 1–12 of 2,117 matching trials for Alzheimer's Disease.
Live ClinicalTrials.gov results.
Phase distribution
Phase 3 7
Phase 2 6
Phase 1 1
Not applicable 1
Top locations
Top sponsors
Top therapies
Live official records
Open in full search- Conditions
- Aging
- Interventions
- Not listed
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 55 Years to 110 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Dementia Moderate, Dementia, Mild, Alzheimer Disease
- Interventions
- Xanamem, Placebo
- Drug
- Lead sponsor
- Actinogen Medical
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 19
- States / cities
- Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more
- Conditions
- Alzheimer's Disease
- Interventions
- VHB937, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment, Healthy
- Interventions
- 18F-PF974, 18F-florbetaben
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Mild Cognitive Impairment, Primary Progressive Aphasia, Dementia
- Interventions
- Computerized Cognitive Training, Active tDCS (tDCS) on DLPFC
- Other · Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Sleep Apnea
- Interventions
- Standard of Care, Personalized OSA Treatment
- Other · Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Early Alzheimer's Disease
- Interventions
- MK-2214, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 36
- States / cities
- Irvine, California • Long Beach, California • Los Angeles, California + 32 more
- Conditions
- Alzheimer's Disease
- Interventions
- No intervention
- Other
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Nutley, New Jersey
- Conditions
- Alzheimer's Disease and Related Dementias, Alzheimer Disease and Related Dementias
- Interventions
- Smart Environmental Light (SmartEnLite)
- Device
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Alzheimer Disease
- Interventions
- Donanemab, Usual Care
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 6,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 1
- States / cities
- Huntsville, Alabama
- Conditions
- Early-Onset Alzheimer Disease
- Interventions
- ALN-APP, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 2
- States / cities
- La Jolla, California • Indianapolis, Indiana
About this Alzheimer's Disease clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.